Recruiting
Phase 1
Phase 2

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Sponsor:

Tango Therapeutics, Inc.

Code:

NCT05732831

Conditions

Locally Advanced Solid Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

TNG462

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information